PARI Aerosol Research Institute Celebrates 100 Years Of Aerosol Therapy
Published: May 17, 2006
MIDLOTHIAN, Va., May 17 /PRNewswire/ -- This month marks PARI's 100 year anniversary in the field of aerosol therapy. Founded in 1906 in Wuppertal, Germany, PARI started out making therapeutic whirlpool baths, evolving into a company focused on helping people with respiratory diseases. Today, the PARI LC Plus and PARI LC Star reusable nebulizers are considered the Gold Standard in aerosol therapy. Numerous pharmaceutical companies have selected PARI products for inclusion in their clinical trials and regulatory approval process including Pulmicort Respules by AstraZeneca; Xopenex by Sepracor; Accuneb and DuoNeb by Dey LP; Pulmozyme by Genentech; and TOBI from Chiron. Fifteen additional clinical development programs are in progress using only PARI products.
Over the company's history, PARI developed the first plastic nebulizers that reduced reproduction costs (1933), patented nozzle technology for greater drug delivery efficiency (1953), and introduced the PARI LC PLUS -- the industry leading breath-enhanced reusable nebulizer. PARI continues to develop new and improved respiratory devices, and in 2005 won a Frost & Sullivan innovation award for the PARI Trek compact compressor.
PARI's key to success has been producing high quality, innovative products that improve the quality of life for patients and their caregivers. Privately funded, PARI will continue to lead in the development of respiratory care by leveraging their expertise in formulation development with novel, customizable product platforms such as the eFlow Electronic Nebulizer, the VibrENT aerosol system for sinuses, and Hydrate humidification technology.
PARI is a leading worldwide developer and manufacturer of fast and efficient aerosol delivery systems for patients with asthma, chronic lung disease, and cystic fibrosis. PARI's primary focus is to provide patients with innovative products and services that help control or prevent symptoms from respiratory diseases. PARI also develops inhalable drug products in the area of chronic lung diseases and already has several drug candidates in clinical development. PARI's worldwide headquarters is in Starnberg, Germany with a major presence in the United States and offices in Japan, United Kingdom, and China.
CONTACT: Kirsten Ayars, +1-805-452-7909, for PARI; or Geoff A. Hunziker ofeFlow LLC, +1-831-372-3580; or Werner Gutmann of PARI RespiratoryEquipment, Inc., +1-804-253-7274, ext. 701